Less Ads, More Data, More Tools Register for FREE

Pin to quick picksM P Evans Regulatory News (MPE)

Share Price Information for M P Evans (MPE)

Share Price is delayed by 15 minutes
Get Live Data
1,482.00    -20.00 (-1.33%)
Bid:
1,468.00
Ask:
1,478.00
Spread: 10.00 (0.681%)
Market Cap: £772.28m
MPE Live PriceLast checked at - London Stock Exchange

Intraday M P Evans Share Chart

Acquisition

6 Mar 2023 07:00

RNS Number : 8974R
M. P. Evans Group PLC
06 March 2023
 

M.P. EVANS GROUP PLC

("The Group" or "M.P.Evans")

 

ACQUISITION OF PLANTED LAND IN INDONESIA

 

The board of M.P.Evans, the producer of sustainable palm oil, is pleased to announce, in line with its growth strategy, the acquisition, for cash, of additional planted land, adjacent to the Group's Simpang Kiri estate, in Indonesia.

 

The Group has been successful in acquiring 100% of the shares in two Indonesian companies, PT Teunggulon Raya and PT Dharma Agung, which between them own 2,100 hectares planted with oil palm. All the land being acquired is fully titled, with long leaseholds already established with the Indonesian government, in a similar way to the Group's existing properties. The planted land is close to the Group's Simpang Kiri estate in Aceh Province, Northern Sumatra. Total costs associated with the acquisition, including the assumption of liabilities within the companies acquired, are estimated to be US$14.3 million, giving rise to a purchase cost of US$6,800 per hectare. The Group does expect to replant some of the acquired areas in the near term, as part of its plans to bring them up to Group standards.

 

Following the acquisition, the Group will have an expanded planted area of 4,800 hectares at or around the Simpang Kiri estate, and the potential to build its own palm-oil mill there. If one is developed, the Group would reach a position of processing 100% of its own crop, as well as further increasing its sustainable palm-oil production.

 

Commenting on the acquisition, Peter Hadsley-Chaplin, executive chairman, said:

 

"This is an excellent acquisition, fully in keeping with our stated strategy and supported by the strength of the Group's balance sheet. Thanks to a combination of the good price at which it has been secured, and the added scale it gives the Group around Simpang Kiri, these additional hectares are further fuel for the M.P.Evans growth engine."

 

6 March 2023

 

Enquiries:

M.P. Evans Group PLC

+44 (0)1892 516333

Peter Hadsley-Chaplin

Executive chairman

Matthew Coulson

Chief executive

Luke Shaw

Chief financial officer

Peel Hunt LLP (Nomad and joint broker)

+44 (0)20 7418 8900

Dan Webster, Andrew Clark, Lalit Bose

finnCap (Joint broker)

+44 (0)20 7220 0500

Tim Redfern, Harriet Ward

Hudson Sandler (Financial PR)

+44 (0)20 7796 4133

Charlie Jack, Francis Kerrigan, Amelia Craddock

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUPUAUWUPWGAW
Date   Source Headline
23rd Jan 20237:00 amRNSTransaction in Own Shares
20th Jan 20237:00 amRNSTransaction in Own Shares
19th Jan 20237:00 amRNSTransaction in Own Shares
18th Jan 20237:00 amRNSTransaction in Own Shares
17th Jan 20239:10 amRNSDirector/PDMR Shareholding
17th Jan 20237:00 amRNSTransaction in Own Shares
16th Jan 20232:01 pmRNSDirector/PDMR Shareholding
16th Jan 20237:00 amRNSTransaction in Own Shares
16th Jan 20237:00 amRNSCrop and production
13th Jan 20237:00 amRNSTransaction in Own Shares
12th Jan 20237:00 amRNSTransaction in Own Shares
10th Jan 20237:00 amRNSTransaction in Own Shares
9th Jan 20237:00 amRNSTransaction in Own Shares
6th Jan 20234:53 pmRNSDirector/PDMR Shareholding
6th Jan 20237:00 amRNSTransaction in Own Shares
5th Jan 20237:00 amRNSTransaction in Own Shares
4th Jan 20237:00 amRNSTransaction in Own Shares
3rd Jan 20233:52 pmRNSBlock listing Interim Review
3rd Jan 202312:08 pmRNSTotal Voting Rights
3rd Jan 20237:00 amRNSTransaction in Own Shares
30th Dec 20227:00 amRNSTransaction in Own Shares
29th Dec 20227:00 amRNSTransaction in Own Shares
28th Dec 20227:00 amRNSTransaction in Own Shares
22nd Dec 20221:07 pmRNSTransaction in Own Shares
22nd Dec 20227:00 amRNSTransaction in Own Shares
21st Dec 20227:00 amRNSTransaction in Own Shares
19th Dec 20227:00 amRNSShare buyback extension
14th Dec 20227:00 amRNSDirector/PDMR Shareholding
12th Dec 20227:00 amRNSTransaction in Own Shares
9th Dec 20227:00 amRNSTransaction in Own Shares
8th Dec 20227:00 amRNSTransaction in Own Shares
7th Dec 20224:17 pmRNSTR1:Standard form - notification of major holdings
1st Dec 20224:40 pmRNSTotal Voting Rights
29th Nov 20227:00 amRNSTransaction in Own Shares
28th Nov 20227:00 amRNSTransaction in Own Shares
25th Nov 20227:00 amRNSTransaction in Own Shares
23rd Nov 20227:00 amRNSTransaction in Own Shares
21st Nov 20227:00 amRNSTransaction in Own Shares
18th Nov 20227:00 amRNSTransaction in Own Shares
16th Nov 20227:00 amRNSTransaction in Own Shares
11th Nov 20227:00 amRNSTransaction in Own Shares
8th Nov 20227:00 amRNSTransaction in Own Shares
4th Nov 20227:00 amRNSTransaction in Own Shares
3rd Nov 20227:00 amRNSTransaction in Own Shares
2nd Nov 20227:00 amRNSTransaction in Own Shares
1st Nov 20224:45 pmRNSTotal Voting Rights
31st Oct 20227:00 amRNSTransaction in Own Shares
28th Oct 20227:00 amRNSTransaction in Own Shares
26th Oct 20227:00 amRNSTransaction in Own Shares
24th Oct 20227:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.